Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TMCI +28.3% (guidance), AXNX +21.3% (guidance), RXST +8.4% (guidance), AKYA +8.3% (guidance), CROX +7.8% (guidance), CALT +5.5% (guidance), ADMA +3.4% (guidance), BCRX +2.6% (guidance), BOOT +2.6% (guidance), EWCZ +2.3% (guidance), NUS +1.9% (guidance), TAST +1.7% (guidance), ANF +1.4% (guidance), RPRX +1.3% (guidance), CTRN +1.3% (guidance), OSW +0.9% (guidance), DXLG +0.8% (guidance), HELE +0.7%
Other news:
- RLAY +8.9% (enters into $30 mln securities purchase agreement for private placement financing with Nextech to sell approximately 2.5 mln shares of common stock at $12.00 per share)
- GLUE +8.5% (Provides Corporate Update and Key Anticipated Milestones for 2024)
- MOLN +8.3% (Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference)
- LGND +5.9% (FDA has approved ZELSUVMI)
- LYRA +4% (releases presentation with data on file as of January 5 2024 from the BEACON Phase 2 clinical trial demonstrating statistically significant improvement in loss of smell in a subset of patients with impaired smell at baseline)
- ANNX +3.2% (Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune Ophthalmic and Neurodegenerative Diseases)
- HUT +3% (received an approval and vesting order related to previously announced stalking horse bid transaction)
- CABA +2.7% (receives additional FDA Fast Track Designations for CABA-201 in dermatomyositis and systemic sclerosis)
- RPTX +2.1% (provides corporate update and highlights anticipated key 2024 milestones)
- LXRX +2% (provides business and pipeline update at 42nd Annual J.P. Morgan Healthcare Conference)
- ABSI +1.9% (will be presenting positive preclinical data for ABS-101 a potential best-in-class anti-TL1A antibody program)
- WRAP +1.4% (terminates CFO Chris DeAlmeida effective immediately)
- ZURA +1.2% (appointments of Robert Lisicki as President and Chief Operating Officer)
- QGEN +1% (receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems; announces plans to return ~$300 million to shareholders)
Analyst comments:
- DASH +3.6% (upgraded to Buy from Hold at Jefferies)
- DELL +2.6% (upgraded to Overweight from Neutral at JP Morgan)
- AQN +2.5% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- EFX +1.3% (upgraded to Buy from Underperform at BofA Securities)
- AON +1.1% (upgraded to Overweight from Neutral at JP Morgan)
- BRO +1% (upgraded to Buy from Neutral at Goldman)
- AAL +0.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AMD +0.8% (upgraded to Buy from Hold at Melius)